Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Jul;28(1):51–54. doi: 10.1128/aac.28.1.51

Efficacy of BMY-28142 in experimental bacteremia and meningitis caused by Escherichia coli and group B streptococci.

K S Kim, A S Bayer
PMCID: PMC176308  PMID: 3899006

Abstract

We evaluated the activity of BMY-28142 against a K1 E. coli strain and a type III group B streptococcal strain in vitro and in vivo and compared the results with those of cefotaxime and penicillin G, respectively. In vitro, the MICs and MBCs of BMY-28142 were close to those of cefotaxime (less than or equal to 2-fold difference) for E. coli and fourfold less than those of penicillin G for group B streptococci. In vivo studies with an experimental bacteremia and meningitis model in newborn rats revealed that the mean penetration of BMY-28142 into the cerebrospinal fluid was 15% that of concomitant levels in serum and that significantly greater bactericidal titers were achieved in blood and cerebrospinal fluid for both test organisms with BMY-28142 than with cefotaxime and penicillin G. However, the overall efficacy of BMY-28142 was similar to that of cefotaxime for the E. coli infection and that of penicillin G for the group B streptococcal infection. This was shown by similar rates of bacterial clearance from blood and cerebrospinal fluid and similar mortality rates. These findings indicate that the activity of BMY-28142 is bactericidal in vitro and in vivo against E. coli and group B streptococci, suggesting that this agent may be a suitable alternative for the therapy of E. coli and group B streptococcal bacteremia and meningitis.

Full text

PDF
54

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodey G. P., Ho D. H., LeBlanc B. In vitro studies of BMY-28142, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1985 Feb;27(2):265–269. doi: 10.1128/aac.27.2.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Del Rio M., McCracken G. H., Jr, Nelson J. D., Chrane D., Shelton S. Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis. Antimicrob Agents Chemother. 1982 Oct;22(4):622–627. doi: 10.1128/aac.22.4.622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Kessler R. E., Bies M., Buck R. E., Chisholm D. R., Pursiano T. A., Tsai Y. H., Misiek M., Price K. E., Leitner F. Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics. Antimicrob Agents Chemother. 1985 Feb;27(2):207–216. doi: 10.1128/aac.27.2.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Khan N. J., Bihl J. A., Schell R. F., LeFrock J. L., Weber S. J. Antimicrobial activities of BMY-28142, cefbuperazone, and cefpiramide compared with those of other cephalosporins. Antimicrob Agents Chemother. 1984 Oct;26(4):585–590. doi: 10.1128/aac.26.4.585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kim K. S., Anthony B. F. Efficacy of trimethoprim/sulfamethoxazole in experimental Escherichia coli bacteremia and meningitis. Chemotherapy. 1983;29(6):428–435. doi: 10.1159/000238231. [DOI] [PubMed] [Google Scholar]
  6. Kim K. S., Anthony B. F. Penicillin tolerance in group B streptococci isolated from infected neonates. J Infect Dis. 1981 Nov;144(5):411–419. doi: 10.1093/infdis/144.5.411. [DOI] [PubMed] [Google Scholar]
  7. Kim K. S., Manocchio M., Anthony B. F. Paradox between the responses of Escherichia coli K1 to ampicillin and chloramphenicol in vitro and in vivo. Antimicrob Agents Chemother. 1984 Nov;26(5):689–693. doi: 10.1128/aac.26.5.689. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kim K. S., Manocchio M., Bayer A. S. Efficacy of cefotaxime and latamoxef for Escherichia coli bacteremia and meningitis in newborn rats. Chemotherapy. 1984;30(4):262–269. doi: 10.1159/000238278. [DOI] [PubMed] [Google Scholar]
  9. Marymont J. H., Jr, Wentz R. M. Serial dilution antibiotic sensitivity testing with the microtitrator system. Am J Clin Pathol. 1966 May;45(5):548–551. doi: 10.1093/ajcp/45.5.548. [DOI] [PubMed] [Google Scholar]
  10. Rosenfeld W. N., Evans H. E., Batheja R., Jhaveri R. C., Vohra K., Khan A. J. Pharmacokinetics of cefoperazone in full-term and premature neonates. Antimicrob Agents Chemother. 1983 Jun;23(6):866–869. doi: 10.1128/aac.23.6.866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Schaad U. B., Stoeckel K. Single-dose pharmacokinetics of ceftriaxone in infants and young children. Antimicrob Agents Chemother. 1982 Feb;21(2):248–253. doi: 10.1128/aac.21.2.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Siegel J. D., McCracken G. H., Jr Sepsis neonatorum. N Engl J Med. 1981 Mar 12;304(11):642–647. doi: 10.1056/NEJM198103123041105. [DOI] [PubMed] [Google Scholar]
  13. Täuber M. G., Doroshow C. A., Hackbarth C. J., Rusnak M. G., Drake T. A., Sande M. A. Antibacterial activity of beta-lactam antibiotics in experimental meningitis due to Streptococcus pneumoniae. J Infect Dis. 1984 Apr;149(4):568–574. doi: 10.1093/infdis/149.4.568. [DOI] [PubMed] [Google Scholar]
  14. Täuber M. G., Hackbarth C. J., Scott K. G., Rusnak M. G., Sande M. A. New cephalosporins cefotaxime, cefpimizole, BMY 28142, and HR 810 in experimental pneumococcal meningitis in rabbits. Antimicrob Agents Chemother. 1985 Mar;27(3):340–342. doi: 10.1128/aac.27.3.340. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES